R&D channel feed – Endpoints News

R&D channel feed

As Moderna doubles down on vaccines, Merck pulls out of a long-running collaboration

5 years ago

After two rounds of mixed data, Eli Lilly impresses analysts with new Covid-19 antibody results. And execs want an EUA now

5 years ago

Medicxi splashes more funding into Janpix's STAT protein degrader program

5 years ago

Jim Allison and Pam Sharma back a Canadian AI upstart seeking to solve the tumor stroma puzzle

5 years ago

Jumping ahead of Merck and others, Bristol Myers declares a PD-1 first in NSCLC

5 years ago

Emmanuelle Charpentier and Jennifer Doudna win the Nobel Prize for groundbreaking CRISPR discovery

5 years ago

Talaris Therapeutics bags another $115M to curb immunosuppression in organ transplant patients

5 years ago

Santhera kicks idebenone DMD program to the curb after PhIII trial fails interim analysis

5 years ago

GSK, Vir cleared to leap into PhIII, angling for a spot in the Covid-19 antibody race led by Lilly, Regeneron

5 years ago

FDA hands Y-mAbs refusal to file letter in one of its pediatric neuroblastoma programs

5 years ago

Amgen posts upbeat assessment of PhII KRAS data on AMG510 — but there's no clear picture of what researchers saw

5 years ago

GSK, AstraZeneca plan to harness AI power for drug development from Nvidia's new, $50M-plus supercomputer now under construction

5 years ago

Neil Kumar bets nearly $1B on what BridgeBio hopes will be their first big drug

5 years ago

After weathering failure, rejection and layoffs, ImmunoGen touts a new 'breakthrough' drug in its comeback plan

5 years ago

Harvard 'MacArthur genius’ Kevin Eggan steps in to run early-stage research at rare disease specialist BioMarin

5 years ago

With Covid-19 mucking the tires, Robert Duggan throws another $50M behind his big antibiotics play

5 years ago

Opdivo/Yervoy combo flops again in melanoma, but Bristol Myers Squibb also has a new OK to celebrate

5 years ago

What happens when the N-of-1 is the president of the US? Regeneron is about to find out

5 years ago

The FDA hands Farxiga 'breakthrough' status in CKD, clearing path for AstraZeneca's much-touted therapy

5 years ago

Merck R&D chief Roger Perlmutter is handing off the big job to the exec in charge of discovery

5 years ago

C4's Andrew Hirsch blows up IPO to $182M, while oncolytic virus upstart nabs $87M offering

5 years ago

With a potential FDA approval looming, G1 Therapeutics taps ex-GSK US president Jack Bailey as new CEO

5 years ago

AMAG tops its year-long, activist driven transformation with a $647M selloff to private equity

5 years ago

Is the future of diabetes drugs in dual GIP and GLP-1 incretin receptor agonists? That's the $47M question for Carmot

5 years ago

First page Previous page 186 187 188189190 191 192 Next page Last page